TITLE

Elevated PTPN2 expression is associated with inferior molecular response in de-novo chronic myeloid leukaemia patients

AUTHOR(S)
Kok, C H; Leclercq, T; Watkins, D B; Saunders, V; Wang, J; Hughes, T P; White, D L
PUB. DATE
March 2014
SOURCE
Leukemia (08876924);Mar2014, Vol. 28 Issue 3, p702
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article presents a study on the association of elevated protein tyrosine phosphatase, non-receptor type 2 (PTPN2) expression in patients with chronic myeloid leukemia (CML). The alternative signalling pathways that might activated in the group of high PTPN2 expression related to poor major molecular response (MMR) rates were also investigated. The results suggest that patients having high PTPN2 expression have increased activation of the ß-catenin pathways.
ACCESSION #
94762957

 

Related Articles

  • MOLECULAR RESPONSE IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA TREATED WITH IMATINIB - SINGLE CENTRE EXPERIENCE. Pavkovic, Marica; Angelkovic, Rosica; Popova-Simjanovska, Marija; Genadieva-Stavric, Sonja; Cevreska, Lidija; Stojanovic, Aleksandar // Prilozi;2015, Vol. 36 Issue 2, p179 

    Introduction of tyrosine kinase inhibitors (TKI) dramatically improves the treatment and survival of the patients with chronic myeloid leukemia (CML) in the last decade. Imatinib (IM) and other TKI induce larger percentage of complete cytogenetic response (CCyR) and major molecular response...

  • Long-term CML management requires routine assessments for toxicities, adherence. Blamble, Debbie // Hem/Onc Today;6/25/2014, Vol. 15 Issue 12, p8 

    The article offers a review of the long-term follow-up of patients suffering from chronic myeloid leukemia (CML) and mentions topics including how patients' response can be monitored, the adverse effects that can result from the use of tyrosine kinase inhibitors (TKI) and the lack of adherence...

  • Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib. Hanfstein, B; Shlyakhto, V; Lauseker, M; Hehlmann, R; Saussele, S; Dietz, C; Erben, P; Fabarius, A; Proetel, U; Schnittger, S; Krause, S W; Schubert, J; Einsele, H; Hänel, M; Dengler, J; Falge, C; Kanz, L; Neubauer, A; Kneba, M; Stegelmann, F // Leukemia (08876924);Oct2014, Vol. 28 Issue 10, p1988 

    Early assessment of response at 3 months of tyrosine kinase inhibitor treatment has become an important tool to predict favorable outcome. We sought to investigate the impact of relative changes of BCR-ABL transcript levels within the initial 3 months of therapy. In order to achieve accurate...

  • Quantitative monitoring of cell clones carrying point mutations in the BCR–ABL tyrosine kinase domain by ligation-dependent polymerase chain reaction (LD–PCR). Preuner, S.; Denk, D.; Frommlet, F.; Nesslboeck, M.; Lion, T. // Leukemia (08876924);Oct2008, Vol. 22 Issue 10, p1956 

    The article discusses the role of tyrosine kinase (TK) inhibitors as the standard treatment for patients with chronic myeloid leukemia (CML). It says that the level of resistance to individual TK inhibitors may vary from slightly reduced sensitivity to total insensitivity. Further, patients...

  • A population study of imatinib in chronic myeloid leukaemia demonstrates lower efficacy than in clinical trials. Lucas, C. M.; Wang, L.; Austin, G. M.; Knight, K.; Watmough, S. J.; Shwe, K. H.; Dasgupta, R.; Butt, Nauman M.; Galvani, D.; Hoyle, C. F.; Seale, J. R. C.; Clark, R. E. // Leukemia (08876924);Oct2008, Vol. 22 Issue 10, p1963 

    The article discusses the significance of imatinib, a tyrosine kinase inihibitor to the patients with chronic myeloid leukaemia (CML). It says that imatinib has become the treatment of choice for newly diagnosed patients in chronic phase. Further, imatinib-treated cohort within the International...

  • Switching-On Adherence in Chronic Myeloid Leukemia. Leader, Avi; Raanani, Pia // Acta Haematologica;Nov2017, Vol. 138 Issue 3, p138 

    The authors reflect on the clinical challenge in the management of chronic myeloid leukemia (CML) due to patients' nonadherence to tyrosine kinase inhibitors (TKI). They cite the retrospective study by Maeda et al. that suggests that switching medications from imatinib to nilotinib may resolve...

  • Improved Drug Adherence in Patients with Chronic Myeloid Leukemia in the Chronic Phase by Switching to Second-Generation Tyrosine Kinase Inhibitors. Maeda, Yasuhiro; Okamoto, Atsushi; Kawaguchi, Shin-ichiro; Konishi, Akiko; Yamamoto, Kenta; Eguchi, Go; Kanai, Yoshitaka; Yamaguchi, Terufumi // Acta Haematologica;Nov2017, Vol. 138 Issue 3, p140 

    The article discusses the improved drug adherence in patients with chronic myeloid leukemia (CML) by switching to second-generation tyrosine kinase inhibitors (TKI). It compared the drug adherence rates from Imatinib (IM) to TKI nilotinib (NILO). It notes that adherence is a critical factor for...

  • Nilotinib.  // Reactions Weekly;7/3/2010, Issue 1308, p27 

    The article describes the case of a 60-year-old man with chronic myeloid leukaemia suffered from a fatal myocardial infarction while taking nilotinib.

  • Lack of complete hematologic response to TKIs associated with poor prognosis in CML. Adams, Stacey L.; Haigh, Christen; Harris, Jason; Lawrence, Leah // Hem/Onc Today;7/25/2009, Vol. 10 Issue 14, p24 

    The article presents information on a study which investigated lack of complete hematologic response to tyrosine kinase inhibitors related to poor prognosis in chronic myeloid leukemia.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics